I don't expect AGN to continue to pursue apaziquone with SPPI in future trials, as they already modified the contract once to decrease their role and duties in the partnerships. But we'll have to wait for confirmation.
Opinions and comments may have been previously posted @BioDueDiligence, at www.biotechduediligence.com, or disseminated to Chimera Research Group subscribers.